Werewolf and Ambros Therapeutics Announce All-Stock Merger and Rebranding to AMBX

Key Facts

In a move reflecting the ongoing consolidation within the biotech sector to streamline research resources, Werewolf Therapeutics and Ambros Therapeutics have entered into a definitive all-stock merger agreement. According to reports, the combined entity will operate under the name Ambros Therapeutics and is expected to trade on the Nasdaq under the new ticker symbol AMBX. The primary strategic goal of the merger is to focus resources on advancing the neridronate development program for Complex Regional Pain Syndrome Type 1 (CRPS-1).

The merger announcement was accompanied by a concurrent, oversubscribed $150 million private placement featuring participation from various institutional investors. Under the terms of the deal, pre-merger Werewolf stockholders are expected to own approximately 6.8% of the combined company, while pre-merger Ambros stockholders will hold roughly 71.7%. Investors from the private placement are slated to own the remaining 21.5%. This structural shift comes as the market increasingly prioritizes biotech firms with advanced-stage clinical programs.

Regarding market performance, updated price levels for the instrument are currently unavailable per market data as of August 21, 2026. Investors are looking toward the formal rebranding and the commencement of trading under the AMBX ticker as the next primary catalysts. Additionally, broader market sentiment may be influenced by upcoming US economic data, including consumer sentiment and retail sales figures, which have recently shown signs of softening.